Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Corrado Campochiaro and Lorenzo Dagna.
Corrado Campochiaro
Connection Strength
8.779
Lorenzo Dagna
  1. Severe acute respiratory syndrome coronavirus-2-induced flare of systemic sclerosis. Scand J Rheumatol. 2022 Mar; 51(2):156-158.
    View in: PubMed
    Score: 0.955
  2. Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. J Clin Rheumatol. 2021 Jun 01; 27(4):e143-e146.
    View in: PubMed
    Score: 0.948
  3. The conundrum of interleukin-6 blockade in COVID-19. Lancet Rheumatol. 2020 Oct; 2(10):e579-e580.
    View in: PubMed
    Score: 0.897
  4. Response to 'Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey'' by Montero et al. Ann Rheum Dis. 2021 Jul 02.
    View in: PubMed
    Score: 0.239
  5. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front Immunol. 2021; 12:675678.
    View in: PubMed
    Score: 0.236
  6. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 Apr; 3(4):e253-e261.
    View in: PubMed
    Score: 0.232
  7. Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey. Ann Rheum Dis. 2021 01 28.
    View in: PubMed
    Score: 0.232
  8. Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. Rheumatology (Oxford). 2021 01 05; 60(1):465-467.
    View in: PubMed
    Score: 0.231
  9. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Front Pharmacol. 2020; 11:598308.
    View in: PubMed
    Score: 0.230
  10. Response to: 'Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey' by Comarmond et al. Ann Rheum Dis. 2020 Nov 12.
    View in: PubMed
    Score: 0.228
  11. Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. Microvasc Res. 2021 01; 133:104071.
    View in: PubMed
    Score: 0.226
  12. Mavrilimumab for severe COVID-19 - Authors' reply. Lancet Rheumatol. 2020 Nov; 2(11):e662-e663.
    View in: PubMed
    Score: 0.225
  13. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli. Ann Rheum Dis. 2020 Jul 31.
    View in: PubMed
    Score: 0.224
  14. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e465-e473.
    View in: PubMed
    Score: 0.222
  15. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 06; 76:43-49.
    View in: PubMed
    Score: 0.221
  16. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun; 2(6):e325-e331.
    View in: PubMed
    Score: 0.220
  17. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis. 2020 09; 79(9):1252-1253.
    View in: PubMed
    Score: 0.220
  18. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2020 01 01; 59(1):171-175.
    View in: PubMed
    Score: 0.215
  19. Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy. J Rheumatol. 2019 10; 46(10):1421-1422.
    View in: PubMed
    Score: 0.208
  20. Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019 Feb 25; 21(1):69.
    View in: PubMed
    Score: 0.203
  21. Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report. Scand J Rheumatol. 2019 03; 48(2):166-167.
    View in: PubMed
    Score: 0.197
  22. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. Eur J Intern Med. 2018 11; 57:e11-e12.
    View in: PubMed
    Score: 0.195
  23. Myocarditis: An Interleukin-1-Mediated Disease? Front Immunol. 2018; 9:1335.
    View in: PubMed
    Score: 0.193
  24. Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. Front Immunol. 2018; 9:1233.
    View in: PubMed
    Score: 0.193
  25. Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? Eur Rev Med Pharmacol Sci. 2018 04; 22(8):2189-2190.
    View in: PubMed
    Score: 0.190
  26. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. Rheumatology (Oxford). 2017 12 01; 56(12):2084-2092.
    View in: PubMed
    Score: 0.186
  27. Intrathecal rituximab for IgG4-related hypertrophic pachymeningitis. J Neurol Neurosurg Psychiatry. 2018 04; 89(4):441-444.
    View in: PubMed
    Score: 0.182
  28. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology. 2017; 6(6):e1318237.
    View in: PubMed
    Score: 0.178
  29. THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. Rheumatology (Oxford). 2021 Jul 28.
    View in: PubMed
    Score: 0.060
  30. Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients. Minerva Anestesiol. 2021 08; 87(8):891-902.
    View in: PubMed
    Score: 0.059
  31. Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group. Ann Rheum Dis. 2021 11; 80(11):1498-1501.
    View in: PubMed
    Score: 0.059
  32. The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. J Clin Med. 2021 May 04; 10(9).
    View in: PubMed
    Score: 0.059
  33. Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave. Eur J Intern Med. 2021 06; 88:144-146.
    View in: PubMed
    Score: 0.058
  34. COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. Lancet Rheumatol. 2021 Mar; 3(3):e166-e168.
    View in: PubMed
    Score: 0.058
  35. Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy. Blood Purif. 2021; 50(1):102-109.
    View in: PubMed
    Score: 0.056
  36. Low prevalence of arrhythmias in clinically stable COVID-19 patients. Pacing Clin Electrophysiol. 2020 08; 43(8):891-893.
    View in: PubMed
    Score: 0.056
  37. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020 10; 79(10):1277-1285.
    View in: PubMed
    Score: 0.056
  38. Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. Ann Intern Med. 2018 12 04; 169(11):819-820.
    View in: PubMed
    Score: 0.049
  39. Long-term clinical outcomes of patients with rheumatoid arthritis and concomitant coronary artery disease. Am J Cardiovasc Dis. 2017; 7(1):9-18.
    View in: PubMed
    Score: 0.044
  40. Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. Oncoimmunology. 2016 Jul; 5(7):e1181244.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.